ADMA Biologics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
ADMA develops plasma-derived human immune globulins and operates an FDA-licensed source-plasma collection center in Georgia. The filing covers the three and six months ended June 30, 2012; interim financial statements are unaudited. The company transitioned from a development-stage company to an operating company in the fourth quarter of 2011 after beginning plasma-center revenue generation.
In February 2012, ADMA completed a reverse merger and a private placement that generated approximately $15.7 million of net cash proceeds. The company’s lead product candidate is RI-001, a plasma-derived immune globulin intended for primary immunodeficiency disease.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2012 | Six Months Ended June 30, 2012 |
|---|---|---|
| Revenue | $230,096 | $234,496 |
| Cost of sales | $141,870 | $144,070 |
| Gross profit | $88,226 | $90,426 |
| Gross margin | 38.3% | 38.6% |
| Operating expenses | $1,294,766 | $2,510,468 |
| Loss from operations | $(1,206,540) | $(2,420,042) |
| Net loss | $(1,206,715) | $(1,804,029) |
| Net margin | (524.5%) | (769.3%) |
| Net loss per share | $(0.26) | $(0.49) |
Revenue was generated by plasma sales from the Georgia collection center, primarily under a June 2012 supply agreement with Biotest Pharmaceuticals. The company had not generated revenue from its therapeutics or research-and-development business.
At June 30, 2012, cash and cash equivalents were $12.9 million, compared with $87,771 at December 31, 2011. Working capital was $13.6 million. Total assets were $15.9 million and total liabilities were $1.2 million. Debt was limited primarily to an $84,000 leasehold improvement loan and a $10,000 current portion; related-party notes payable were eliminated through repayment or conversion into equity.
Net cash used in operating activities was $3.0 million for the six months ended June 30, 2012, compared with $986,000 in the prior-year period. Investing cash use was $56,151. Financing activities provided $15.9 million, principally from the February private placement, net of equity issuance costs and debt repayment.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $230,096 for the quarter and $234,496 for the six-month period, reflecting plasma-center sales.
- Gross profit was $88,226 for the quarter and $90,426 for the six-month period; no comparable gross profit was reported in 2011.
- Quarterly net loss improved 49.5%, from $2.4 million to $1.2 million. Six-month net loss improved 54.5%, from $4.0 million to $1.8 million.
- Research and development expense declined 32.6% for the six-month period, to $260,494, while quarterly R&D expense increased 27.9% to $178,674 in preparation for the planned Phase III study.
- The prior-year periods included non-recurring losses on the sale of research-and-development inventory of $1.3 million for the quarter and $1.9 million for six months; no such losses occurred in 2012.
- General and administrative expense increased 110.3% for the six-month period to $1.4 million, driven by merger-related legal, accounting and SEC costs, expanded staffing and stock-based compensation.
- Interest expense declined materially following the conversion or repayment of notes, from $240,026 to $3,098 for the quarter and from $556,164 to $11,592 for six months.
- Shares outstanding increased to 4,654,303 at June 30, 2012 from 408,589 at December 31, 2011, primarily because of the merger, preferred-stock conversion, private placement and note conversion.
Guidance, Outlook, Risks and Unusual Items
Management expected available cash to fund operating, research and development, and capital expenditures into the third quarter of 2013. However, management also stated that additional capital would be required before then because FDA approval of RI-001 was not expected before the second quarter of 2015, if at all. The company had no existing commitments for future external funding.
Key risks include the need for additional financing, potential dilution from future equity offerings, increased fixed obligations from debt, uncertainty regarding clinical-trial timing and outcomes, manufacturing and regulatory delays, and the possibility that RI-001 will not receive FDA approval or become commercially viable. Failure to obtain financing could require the company to delay, reduce or discontinue development programs and clinical trials.
The company received a $617,615 benefit from the sale of New Jersey net operating losses during January 2012. The proceeds are subject to use and continuing-New-Jersey-operations requirements, and may be subject to repayment if those conditions are not met.
Management disclosed a material weakness in internal control over financial reporting related to inadequate segregation of duties in the financial reporting area. Previously reported weaknesses involving the financial-statement closing process and accounting expertise were described as remediated through, among other actions, the hiring of a chief financial officer.
Subsequent events included the appointment of a new director and the hiring of a chief scientific officer and chief medical officer, together with related stock-option grants and employment arrangements.
Important Facts for Investors to Verify
- Whether the Biotest plasma supply agreement produces sustained revenue and improves plasma-center profitability.
- The timing, design, enrollment and results of the planned Phase III trial for RI-001, and the FDA’s expected approval timeline.
- The company’s actual cash burn and whether the projected runway to the third quarter of 2013 remains valid.
- The timing and terms of required future financing, including potential equity dilution or debt covenants.
- Whether the material weakness related to segregation of duties is remediated and independently validated in subsequent filings.
- Potential repayment obligations associated with the New Jersey net operating loss proceeds.
- Outstanding options and warrants, including their potential dilution to common stockholders.